Search results
Results from the WOW.Com Content Network
AIDS is a peer-reviewed scientific journal that is published by Lippincott Williams & Wilkins. It was established in 1987 and is an official journal of the International AIDS Society. [1] It covers all aspects of HIV and AIDS, including basic science, clinical trials, epidemiology, and social science. The editor in chief is Jay A. Levy ...
Current HIV Research is a peer-reviewed scientific journal focusing on HIV/AIDS research, established in 2003. The journal is edited by Yuntao Wu and is published by Bentham Science Publishers . It has an impact factor of 1.581
HIV/AIDS: Research and Palliative Care is a peer-reviewed medical journal covering HIV and its treatment. The journal was established in 2009 and is published by Dove Medical Press . It is abstracted and indexed in PubMed , EMBASE , EmCare , and Scopus .
HIV Medicine is a bimonthly peer-reviewed medical journal covering HIV/AIDS research. It was established in 1999 and is published by Wiley-Blackwell on behalf of the British HIV Association, of which it is the official journal. It is also the official journal of the European AIDS Clinical Society and the Australasian Society for HIV Medicine. [1]
Scanning electron micrograph of HIV-1, colored green, budding from a cultured lymphocyte Diagram of HIV. HIV/AIDS research includes all medical research that attempts to prevent, treat, or cure HIV/AIDS, as well as fundamental research about the nature of HIV as an infectious agent and AIDS as the disease caused by HIV.
HIV-1 protease is one of the best known aspartic proteases, and an attractive target for the treatment of AIDS. [9] After the discovery of HIV protease it only took 10 years for its first inhibitor to reach the market. [10] The first reports of highly selective antagonists against the HIV protease were
The combination of Rekambys and Vocabria injection is intended for maintenance treatment of adults who have undetectable HIV levels in the blood (viral load less than 50 copies/ml) with their current ARV treatment, and when the virus has not developed resistance to certain class of anti-HIV medicines called non-nucleoside reverse transcriptase ...
In July 2017, The Lancet released an article revealing the results of a study conducted involving an injectable HIV-1 treatment to serve as a future replacement for the three-drug oral combination therapy. This new treatment would consist of two drugs: cabotegravir and rilpivirine, and injections would occur every four to eight weeks for each ...